patisiran (ALN-TTR02)
ALN-TTR02-005
Phase 1 small_molecule completed
Quick answer
patisiran (ALN-TTR02) for Transthyretin (TTR)-Mediated Amyloidosis is a Phase 1 program (small_molecule) at ALNYLAM PHARMACEUTICALS, INC. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- ALNYLAM PHARMACEUTICALS, INC.
- Indication
- Transthyretin (TTR)-Mediated Amyloidosis
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- completed